Perrigo Company plc OCI, before Reclassifications, Net of Tax, Attributable to Parent
Perrigo Company plc (PRGO) reported OCI, before Reclassifications, Net of Tax, Attributable to Parent of -$10.20 million for the 6-month period ending 2026-06-27, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OciBeforeReclassificationsNetOfTaxAttributableToParent · last filed 2026-08-05
- Perrigo Company plc oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2026-06-27 was -$2.90M, a 101.93% decline year-over-year.
- Perrigo Company plc oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2026-03-28 was -$7.30M, a 107.52% decline year-over-year.
- Perrigo Company plc oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2025-12-31 was -$63.00M.
- Perrigo Company plc oci, before reclassifications, net of tax, attributable to parent for the quarter ending 2025-09-27 was -$1.70M, a 102.33% decline year-over-year.
- Perrigo Company plc oci, before reclassifications, net of tax, attributable to parent for fiscal 2025 was $182.30M.
- Perrigo Company plc oci, before reclassifications, net of tax, attributable to parent for fiscal 2024 was -$133.50M.
- Perrigo Company plc oci, before reclassifications, net of tax, attributable to parent for fiscal 2022 was -$12.30M.
- Perrigo Company plc oci, before reclassifications, net of tax, attributable to parent for fiscal 2021 was -$357.40M, a 264.25% decline from fiscal 2020.
| Period end | OCI, before Reclassifications, Net of Tax, Attributable to Parent 3 month | OCI, before Reclassifications, Net of Tax, Attributable to Parent 6 month | OCI, before Reclassifications, Net of Tax, Attributable to Parent 9 month | OCI, before Reclassifications, Net of Tax, Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-06-27 | -$2.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | -$10.20M 10-Q · filed 2026-08-05 | -$73.20M derived: sum of 3 quarters · filed 2026-08-05 | -$74.90M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-28 | -$7.30M 10-Q · filed 2026-05-06 | -$70.30M derived: sum of 2 quarters · filed 2026-05-06 | -$72.00M derived: sum of 3 quarters · filed 2026-05-06 | $77.90M derived: sum of 4 quarters · filed 2026-05-06 |
| 2025-12-31 | -$63.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$64.70M derived: sum of 2 quarters · filed 2026-02-26 | $85.20M derived: sum of 3 quarters · filed 2026-02-26 | $182.30M 10-K · filed 2026-02-26 |
| 2025-09-27 | -$1.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $148.20M derived: sum of 2 quarters · filed 2025-11-05 | $245.30M 10-Q · filed 2025-11-05 | $87.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-06-28 | $149.90M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $247.00M 10-Q · filed 2025-08-06 | $89.20M derived: sum of 3 quarters · filed 2026-02-26 | $162.10M derived: sum of 4 quarters · filed 2026-02-26 |
| 2025-03-29 | $97.10M 10-Q · filed 2025-05-07 | -$60.70M derived: sum of 2 quarters · filed 2026-02-26 | $12.20M derived: sum of 3 quarters · filed 2026-02-26 | $4.40M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-12-31 | -$157.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$84.90M derived: sum of 2 quarters · filed 2026-02-26 | -$92.70M derived: sum of 3 quarters · filed 2026-02-26 | -$133.50M 10-K · filed 2026-02-26 |
| 2024-09-28 | $72.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $65.10M derived: sum of 2 quarters · filed 2024-11-06 | $24.30M 10-Q · filed 2024-11-06 | |
| 2024-06-29 | -$7.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-02 | -$48.60M 10-Q · filed 2024-08-02 | ||
| 2024-03-30 | -$40.80M 10-Q · filed 2024-05-07 | |||
| 2023-09-30 | -$91.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$58.30M derived: sum of 2 quarters · filed 2023-11-07 | -$34.50M 10-Q · filed 2023-11-07 | $260.10M derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-07-01 | $33.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $57.00M 10-Q · filed 2023-08-08 | $351.60M derived: sum of 3 quarters · filed 2023-08-08 | $187.70M derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-04-01 | $23.80M 10-Q · filed 2023-05-09 | $318.40M derived: sum of 2 quarters · filed 2023-05-09 | $154.50M derived: sum of 3 quarters · filed 2023-05-09 | -$9.60M derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | $294.60M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $130.70M derived: sum of 2 quarters · filed 2023-02-28 | -$33.40M derived: sum of 3 quarters · filed 2023-02-28 | -$12.30M 10-K · filed 2023-02-28 |
| 2022-10-01 | -$163.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | -$328.00M derived: sum of 2 quarters · filed 2022-11-08 | -$306.90M 10-Q · filed 2022-11-08 | -$481.20M derived: sum of 4 quarters · filed 2023-02-28 |
| 2022-07-02 | -$164.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | -$143.00M 10-Q · filed 2022-08-09 | -$317.30M derived: sum of 3 quarters · filed 2023-02-28 | -$412.50M derived: sum of 4 quarters · filed 2023-02-28 |
| 2022-04-02 | $21.10M 10-Q · filed 2022-05-11 | -$153.20M derived: sum of 2 quarters · filed 2023-02-28 | -$248.40M derived: sum of 3 quarters · filed 2023-02-28 | -$215.20M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-12-31 | -$174.30M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$269.50M derived: sum of 2 quarters · filed 2023-02-28 | -$236.30M derived: sum of 3 quarters · filed 2023-02-28 | -$357.40M 10-K · filed 2023-02-28 |
| 2021-10-02 | -$95.20M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | -$62.00M derived: sum of 2 quarters · filed 2021-11-12 | -$183.10M 10-Q · filed 2021-11-12 | $15.40M derived: sum of 4 quarters · filed 2022-03-01 |
| 2021-07-03 | $33.20M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-11 | -$87.90M 10-Q · filed 2021-08-11 | $110.60M derived: sum of 3 quarters · filed 2022-03-01 | $193.00M derived: sum of 4 quarters · filed 2022-03-01 |
| 2021-04-03 | -$121.10M 10-Q · filed 2021-05-12 | $77.40M derived: sum of 2 quarters · filed 2022-03-01 | $159.80M derived: sum of 3 quarters · filed 2022-03-01 | $198.60M derived: sum of 4 quarters · filed 2022-03-01 |
| 2020-12-31 | $198.50M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $280.90M derived: sum of 2 quarters · filed 2022-03-01 | $319.70M derived: sum of 3 quarters · filed 2022-03-01 | $217.60M 10-K · filed 2022-03-01 |
| 2020-09-26 | $82.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $121.20M derived: sum of 2 quarters · filed 2020-11-05 | $19.10M 10-Q · filed 2020-11-05 | |
| 2020-06-27 | $38.80M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-05 | -$63.30M 10-Q · filed 2020-08-05 | ||
| 2020-03-28 | -$102.10M 10-Q · filed 2020-05-05 | |||
| 2019-12-31 | $60.10M 10-K · filed 2021-03-01 | |||
| 2018-12-31 | -$163.40M 10-K · filed 2020-02-27 | |||
| 2017-12-31 | $338.10M 10-K · filed 2019-02-27 | |||
| 2016-12-31 | -$64.50M 10-K · filed 2018-03-01 | |||
| 2015-12-31 | -$129.10M 10-K · filed 2018-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |